Chronic hepatitis C virus (HCV) burden in Rhode Island: modelling treatment scale-up and elimination
We utilized a disease progression model to predict the number of viraemic infections, cirrhotic cases, and liver-related deaths in the state of Rhode Island (RI) under four treatment scenarios: (1) current HCV treatment paradigm (about 215 patients treated annually, Medicaid reimbursement criteria f...
Gespeichert in:
| Veröffentlicht in: | Epidemiology and infection 2016-12, Vol.144 (16), p.3376-3386 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 3386 |
|---|---|
| container_issue | 16 |
| container_start_page | 3376 |
| container_title | Epidemiology and infection |
| container_volume | 144 |
| creator | SOIPE, A. I. RAZAVI, H. RAZAVI-SHEARER, D. GALÁRRAGA, O. TAYLOR, L. E. MARSHALL, B. D. L. |
| description | We utilized a disease progression model to predict the number of viraemic infections, cirrhotic cases, and liver-related deaths in the state of Rhode Island (RI) under four treatment scenarios: (1) current HCV treatment paradigm (about 215 patients treated annually, Medicaid reimbursement criteria fibrosis stage ⩾F3); (2) immediate scale-up of treatment (to 430 annually) and less restrictive Medicaid reimbursement criteria (fibrosis stage ⩾F2); (3) immediate treatment scale-up and no fibrosis stage-specific Medicaid reimbursement criteria (⩾F0); (4) an ‘elimination’ scenario (i.e. a continued treatment scale-up needed to achieve >90% reduction in viraemic cases by 2030). Under current treatment models, the number of cirrhotic cases and liver-related deaths will plateau and peak by 2030, respectively. Treatment scale-up with ⩾F2 and ⩾F0 fibrosis stage treatment criteria could reduce the number of cirrhotic cases by 21·7% and 10·0%, and the number of liver-related deaths by 19·3% and 7·4%, respectively by 2030. To achieve a >90% reduction in viraemic cases by 2030, over 2000 persons will need to be treated annually by 2020. This strategy could reduce cirrhosis cases and liver-related deaths by 78·9% and 72·4%, respectively by 2030. Increased HCV treatment uptake is needed to substantially reduce the burden of HCV by 2030 in Rhode Island. |
| doi_str_mv | 10.1017/S0950268816001722 |
| format | Article |
| fullrecord | <record><control><sourceid>jstor_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5562531</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><cupid>10_1017_S0950268816001722</cupid><jstor_id>26515867</jstor_id><sourcerecordid>26515867</sourcerecordid><originalsourceid>FETCH-LOGICAL-c596t-e6f96f548dce428f8f99c59fca4b1f6919af8360cf029b7174260e3695953e453</originalsourceid><addsrcrecordid>eNqFkV9rFDEUxYModlv9AD4oAV_qw9Qkk2QSHwQZtC0UBP-9hsxMsptlJlmTTMFv3wy7tlUpPoXL-d1z780B4AVGZxjh5u1XJBkiXAjMUakJeQRWmHJZUYrkY7Ba5GrRj8BxSluEkCSieQqOSEMlwZSswNBuYvCuhxuz09lll2ALr12cEzy9aH-8gd0cB-Oh8_DLJgwGXqZR--EdnEoxjs6vYY5G58n4DFOvR1PNO1gIaEY3OV88g38Gnlg9JvP88J6A758-fmsvqqvP55fth6uqZ5LnynAruWVUDL2hRFhhpSyK7TXtsOUSS21FzVFvEZFdgxtKODI1l0yy2lBWn4D3e9_d3E2muPgc9ah20U06_lJBO_Wn4t1GrcO1YowTVuNicHowiOHnbFJWk0t9uVN7E-aksEScMikw-T8qmGww4mRBX_-FbsMcffmJQtWsETVGC4X3VB9DStHY270xUkvc6p-4S8-r-wffdvzOtwAv98A25RDvdM4wE7wpen0YqqcuumFt7u324NgbyBm9HQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1835783102</pqid></control><display><type>article</type><title>Chronic hepatitis C virus (HCV) burden in Rhode Island: modelling treatment scale-up and elimination</title><source>JSTOR Archive Collection A-Z Listing</source><source>PubMed Central</source><creator>SOIPE, A. I. ; RAZAVI, H. ; RAZAVI-SHEARER, D. ; GALÁRRAGA, O. ; TAYLOR, L. E. ; MARSHALL, B. D. L.</creator><creatorcontrib>SOIPE, A. I. ; RAZAVI, H. ; RAZAVI-SHEARER, D. ; GALÁRRAGA, O. ; TAYLOR, L. E. ; MARSHALL, B. D. L.</creatorcontrib><description>We utilized a disease progression model to predict the number of viraemic infections, cirrhotic cases, and liver-related deaths in the state of Rhode Island (RI) under four treatment scenarios: (1) current HCV treatment paradigm (about 215 patients treated annually, Medicaid reimbursement criteria fibrosis stage ⩾F3); (2) immediate scale-up of treatment (to 430 annually) and less restrictive Medicaid reimbursement criteria (fibrosis stage ⩾F2); (3) immediate treatment scale-up and no fibrosis stage-specific Medicaid reimbursement criteria (⩾F0); (4) an ‘elimination’ scenario (i.e. a continued treatment scale-up needed to achieve >90% reduction in viraemic cases by 2030). Under current treatment models, the number of cirrhotic cases and liver-related deaths will plateau and peak by 2030, respectively. Treatment scale-up with ⩾F2 and ⩾F0 fibrosis stage treatment criteria could reduce the number of cirrhotic cases by 21·7% and 10·0%, and the number of liver-related deaths by 19·3% and 7·4%, respectively by 2030. To achieve a >90% reduction in viraemic cases by 2030, over 2000 persons will need to be treated annually by 2020. This strategy could reduce cirrhosis cases and liver-related deaths by 78·9% and 72·4%, respectively by 2030. Increased HCV treatment uptake is needed to substantially reduce the burden of HCV by 2030 in Rhode Island.</description><identifier>ISSN: 0950-2688</identifier><identifier>EISSN: 1469-4409</identifier><identifier>DOI: 10.1017/S0950268816001722</identifier><identifier>PMID: 27492142</identifier><language>eng</language><publisher>Cambridge, UK: Cambridge University Press</publisher><subject>Age ; Baby boomers ; Cancer therapies ; Estimates ; Gender ; Health surveillance ; Hepatitis ; Hepatitis C ; Hepatitis C virus ; Infections ; Infectious diseases ; Liver cancer ; Liver cirrhosis ; Liver diseases ; Medicaid ; Mortality ; Original Papers ; Project evaluation</subject><ispartof>Epidemiology and infection, 2016-12, Vol.144 (16), p.3376-3386</ispartof><rights>Copyright © Cambridge University Press 2016</rights><rights>Cambridge University Press 2016</rights><rights>Cambridge University Press 2016 2016 Cambridge University Press</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c596t-e6f96f548dce428f8f99c59fca4b1f6919af8360cf029b7174260e3695953e453</citedby><cites>FETCH-LOGICAL-c596t-e6f96f548dce428f8f99c59fca4b1f6919af8360cf029b7174260e3695953e453</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.jstor.org/stable/pdf/26515867$$EPDF$$P50$$Gjstor$$H</linktopdf><linktohtml>$$Uhttps://www.jstor.org/stable/26515867$$EHTML$$P50$$Gjstor$$H</linktohtml><link.rule.ids>230,314,727,780,784,803,885,27924,27925,53791,53793,58017,58250</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27492142$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>SOIPE, A. I.</creatorcontrib><creatorcontrib>RAZAVI, H.</creatorcontrib><creatorcontrib>RAZAVI-SHEARER, D.</creatorcontrib><creatorcontrib>GALÁRRAGA, O.</creatorcontrib><creatorcontrib>TAYLOR, L. E.</creatorcontrib><creatorcontrib>MARSHALL, B. D. L.</creatorcontrib><title>Chronic hepatitis C virus (HCV) burden in Rhode Island: modelling treatment scale-up and elimination</title><title>Epidemiology and infection</title><addtitle>Epidemiol. Infect</addtitle><description>We utilized a disease progression model to predict the number of viraemic infections, cirrhotic cases, and liver-related deaths in the state of Rhode Island (RI) under four treatment scenarios: (1) current HCV treatment paradigm (about 215 patients treated annually, Medicaid reimbursement criteria fibrosis stage ⩾F3); (2) immediate scale-up of treatment (to 430 annually) and less restrictive Medicaid reimbursement criteria (fibrosis stage ⩾F2); (3) immediate treatment scale-up and no fibrosis stage-specific Medicaid reimbursement criteria (⩾F0); (4) an ‘elimination’ scenario (i.e. a continued treatment scale-up needed to achieve >90% reduction in viraemic cases by 2030). Under current treatment models, the number of cirrhotic cases and liver-related deaths will plateau and peak by 2030, respectively. Treatment scale-up with ⩾F2 and ⩾F0 fibrosis stage treatment criteria could reduce the number of cirrhotic cases by 21·7% and 10·0%, and the number of liver-related deaths by 19·3% and 7·4%, respectively by 2030. To achieve a >90% reduction in viraemic cases by 2030, over 2000 persons will need to be treated annually by 2020. This strategy could reduce cirrhosis cases and liver-related deaths by 78·9% and 72·4%, respectively by 2030. Increased HCV treatment uptake is needed to substantially reduce the burden of HCV by 2030 in Rhode Island.</description><subject>Age</subject><subject>Baby boomers</subject><subject>Cancer therapies</subject><subject>Estimates</subject><subject>Gender</subject><subject>Health surveillance</subject><subject>Hepatitis</subject><subject>Hepatitis C</subject><subject>Hepatitis C virus</subject><subject>Infections</subject><subject>Infectious diseases</subject><subject>Liver cancer</subject><subject>Liver cirrhosis</subject><subject>Liver diseases</subject><subject>Medicaid</subject><subject>Mortality</subject><subject>Original Papers</subject><subject>Project evaluation</subject><issn>0950-2688</issn><issn>1469-4409</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNqFkV9rFDEUxYModlv9AD4oAV_qw9Qkk2QSHwQZtC0UBP-9hsxMsptlJlmTTMFv3wy7tlUpPoXL-d1z780B4AVGZxjh5u1XJBkiXAjMUakJeQRWmHJZUYrkY7Ba5GrRj8BxSluEkCSieQqOSEMlwZSswNBuYvCuhxuz09lll2ALr12cEzy9aH-8gd0cB-Oh8_DLJgwGXqZR--EdnEoxjs6vYY5G58n4DFOvR1PNO1gIaEY3OV88g38Gnlg9JvP88J6A758-fmsvqqvP55fth6uqZ5LnynAruWVUDL2hRFhhpSyK7TXtsOUSS21FzVFvEZFdgxtKODI1l0yy2lBWn4D3e9_d3E2muPgc9ah20U06_lJBO_Wn4t1GrcO1YowTVuNicHowiOHnbFJWk0t9uVN7E-aksEScMikw-T8qmGww4mRBX_-FbsMcffmJQtWsETVGC4X3VB9DStHY270xUkvc6p-4S8-r-wffdvzOtwAv98A25RDvdM4wE7wpen0YqqcuumFt7u324NgbyBm9HQ</recordid><startdate>20161201</startdate><enddate>20161201</enddate><creator>SOIPE, A. I.</creator><creator>RAZAVI, H.</creator><creator>RAZAVI-SHEARER, D.</creator><creator>GALÁRRAGA, O.</creator><creator>TAYLOR, L. E.</creator><creator>MARSHALL, B. D. L.</creator><general>Cambridge University Press</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7T2</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>7U2</scope><scope>5PM</scope></search><sort><creationdate>20161201</creationdate><title>Chronic hepatitis C virus (HCV) burden in Rhode Island: modelling treatment scale-up and elimination</title><author>SOIPE, A. I. ; RAZAVI, H. ; RAZAVI-SHEARER, D. ; GALÁRRAGA, O. ; TAYLOR, L. E. ; MARSHALL, B. D. L.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c596t-e6f96f548dce428f8f99c59fca4b1f6919af8360cf029b7174260e3695953e453</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Age</topic><topic>Baby boomers</topic><topic>Cancer therapies</topic><topic>Estimates</topic><topic>Gender</topic><topic>Health surveillance</topic><topic>Hepatitis</topic><topic>Hepatitis C</topic><topic>Hepatitis C virus</topic><topic>Infections</topic><topic>Infectious diseases</topic><topic>Liver cancer</topic><topic>Liver cirrhosis</topic><topic>Liver diseases</topic><topic>Medicaid</topic><topic>Mortality</topic><topic>Original Papers</topic><topic>Project evaluation</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>SOIPE, A. I.</creatorcontrib><creatorcontrib>RAZAVI, H.</creatorcontrib><creatorcontrib>RAZAVI-SHEARER, D.</creatorcontrib><creatorcontrib>GALÁRRAGA, O.</creatorcontrib><creatorcontrib>TAYLOR, L. E.</creatorcontrib><creatorcontrib>MARSHALL, B. D. L.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nursing & Allied Health Database</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>Safety Science and Risk</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Epidemiology and infection</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>SOIPE, A. I.</au><au>RAZAVI, H.</au><au>RAZAVI-SHEARER, D.</au><au>GALÁRRAGA, O.</au><au>TAYLOR, L. E.</au><au>MARSHALL, B. D. L.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Chronic hepatitis C virus (HCV) burden in Rhode Island: modelling treatment scale-up and elimination</atitle><jtitle>Epidemiology and infection</jtitle><addtitle>Epidemiol. Infect</addtitle><date>2016-12-01</date><risdate>2016</risdate><volume>144</volume><issue>16</issue><spage>3376</spage><epage>3386</epage><pages>3376-3386</pages><issn>0950-2688</issn><eissn>1469-4409</eissn><abstract>We utilized a disease progression model to predict the number of viraemic infections, cirrhotic cases, and liver-related deaths in the state of Rhode Island (RI) under four treatment scenarios: (1) current HCV treatment paradigm (about 215 patients treated annually, Medicaid reimbursement criteria fibrosis stage ⩾F3); (2) immediate scale-up of treatment (to 430 annually) and less restrictive Medicaid reimbursement criteria (fibrosis stage ⩾F2); (3) immediate treatment scale-up and no fibrosis stage-specific Medicaid reimbursement criteria (⩾F0); (4) an ‘elimination’ scenario (i.e. a continued treatment scale-up needed to achieve >90% reduction in viraemic cases by 2030). Under current treatment models, the number of cirrhotic cases and liver-related deaths will plateau and peak by 2030, respectively. Treatment scale-up with ⩾F2 and ⩾F0 fibrosis stage treatment criteria could reduce the number of cirrhotic cases by 21·7% and 10·0%, and the number of liver-related deaths by 19·3% and 7·4%, respectively by 2030. To achieve a >90% reduction in viraemic cases by 2030, over 2000 persons will need to be treated annually by 2020. This strategy could reduce cirrhosis cases and liver-related deaths by 78·9% and 72·4%, respectively by 2030. Increased HCV treatment uptake is needed to substantially reduce the burden of HCV by 2030 in Rhode Island.</abstract><cop>Cambridge, UK</cop><pub>Cambridge University Press</pub><pmid>27492142</pmid><doi>10.1017/S0950268816001722</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0950-2688 |
| ispartof | Epidemiology and infection, 2016-12, Vol.144 (16), p.3376-3386 |
| issn | 0950-2688 1469-4409 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5562531 |
| source | JSTOR Archive Collection A-Z Listing; PubMed Central |
| subjects | Age Baby boomers Cancer therapies Estimates Gender Health surveillance Hepatitis Hepatitis C Hepatitis C virus Infections Infectious diseases Liver cancer Liver cirrhosis Liver diseases Medicaid Mortality Original Papers Project evaluation |
| title | Chronic hepatitis C virus (HCV) burden in Rhode Island: modelling treatment scale-up and elimination |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-30T23%3A46%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstor_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Chronic%20hepatitis%20C%20virus%20(HCV)%20burden%20in%20Rhode%20Island:%20modelling%20treatment%20scale-up%20and%20elimination&rft.jtitle=Epidemiology%20and%20infection&rft.au=SOIPE,%20A.%20I.&rft.date=2016-12-01&rft.volume=144&rft.issue=16&rft.spage=3376&rft.epage=3386&rft.pages=3376-3386&rft.issn=0950-2688&rft.eissn=1469-4409&rft_id=info:doi/10.1017/S0950268816001722&rft_dat=%3Cjstor_pubme%3E26515867%3C/jstor_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1835783102&rft_id=info:pmid/27492142&rft_cupid=10_1017_S0950268816001722&rft_jstor_id=26515867&rfr_iscdi=true |